TCGA-BB-4223-01A-01R-1436-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.390
- SPERMATOGENESIS+0.380
- G2M_CHECKPOINT+0.250
- MITOTIC_SPINDLE+0.130
- APICAL_SURFACE+0.060
- KRAS_SIGNALING_DN+0.050
- ALLOGRAFT_REJECTION-0.030
- BILE_ACID_METABOLISM-0.040
- MYC_TARGETS_V1-0.070
- MYC_TARGETS_V2-0.110
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.530
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.520
- INTERFERON_ALPHA_RESPONSE-0.510
- CHOLESTEROL_HOMEOSTASIS-0.500
- TNFA_SIGNALING_VIA_NFKB-0.460
- MTORC1_SIGNALING-0.450
- MYOGENESIS-0.450
- APOPTOSIS-0.410
- INTERFERON_GAMMA_RESPONSE-0.410
- GLYCOLYSIS-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-DQ-7591-01A-11R-2081-07 | — | — | 0.954 |
| 2 | SRR934905 | — | — | 0.936 |
| 3 | BS_W311713R | medulloblastoma | — | 0.928 |
| 4 | SRR934973 | — | — | 0.927 |
| 5 | SAMN03290905 | — | — | 0.918 |
| 6 | TCGA-FJ-A3ZF-01A-11R-A23N-07 | — | — | 0.910 |
| 7 | BS_VVFBW0YH | medulloblastoma | — | 0.910 |
| 8 | BS_3NWQXPQV | medulloblastoma | — | 0.909 |
| 9 | SRR934771 | — | — | 0.909 |
| 10 | BS_NZ71XCG3 | medulloblastoma | — | 0.907 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 6 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.390 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.380 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.250 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.130 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.060 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.050 | Remibrutinib | — uncovered |